medigraphic.com
ISSN 1561-3100 (Print)

2017, Number 1

<< Back Next >>

Revista Cubana de Ortopedia y Traumatología 2017; 31 (1)

Update on prevention and treatment of surgical blood loss

Tabares NH, Díaz QJM, Tabares SH, Tabares SL

Language: Spanish
References: 73
Page: 92-109
PDF size: 262.75 Kb.


ABSTRACT

Surgical blood loss is one of the biggest challenges facing surgeons today. The demand for highly complex surgeries has increased for multiple reasons. A review was made of the main factors that influence blood loss at each stage of surgery, with emphasis on orthopedic surgical procedures. Existing hemostatic drugs that help prevent such loss and avoid the risk of transfusion were examined and evaluated. Various factors such as anemia, advanced age, the existence of comorbidities, prolonged surgical time, the use in the postoperative of medicines in order to achieve anticoagulation, favor surgical blood loss and elevate blood transfusion rates. The use of hemostatic agents should be based on the clinical sense of the expected therapeutic efficacy, safety against possible complications and the economic costs of its administration.


REFERENCES

  1. Acosta JA, Yang JC, Winchell RJl. Lethal injuries and time to death in a level I trauma center. J Am Coll Surg. 1998;186:528-33.

  2. Mannucci PM, Levi M. Prevention and Treatment of Major Blood Loss. N Engl J Med. 2007;356:22.

  3. Cherian JJ, Kapadia BH, Issa K, Banerjee S, McInerney VK, Harwin SF, et al. Preoperative blood management strategies for total hip arthroplasty. Surg Technol Int. 2013;23:261-6.

  4. Sabatini L, Atzori F, Revello S, Scotti L, Debiasi F, Massè A. et al. Intravenous use of tranexamic acid reduces postoperative blood loss in total knee arthroplasty. Arch Orthop Trauma Surg. 2014;134(11):1609-14.

  5. Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, et al. Topical (intraarticular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). J Bone Joint Surg Am. 2013;95(21):1969-74.

  6. Ha CW, Noh MJ, Choi KB, Lee, KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy. 012;14(2):247-56.

  7. Sizer SC, Cherian JJ, Elmallah R, Pierce TP, Beaver WB, Mont MA. Predicting blood loss in total knee and hip arthroplasty. Orthop Clin N Am. 2015; 46:445-59.

  8. Storer SK, Vitale MG, Hyman JE, Lee FY, Choe JC, Roye DP Jr. Correction of adolescent idiopathic scoliosis using thoracic pedicle screw fixation versus hook constructs. Journal of pediatric orthopedics. 2005;25(4):415-9.

  9. Bjerkreim I, Steen H, Brox JI. Idiopathic scoliosis treated with Cotrel-Dubousset instrumentation: evaluation 10 years after surgery. Spine. 2007; 32(19):2103-10.

  10. Doi T, Harimaya K, Matsumoto Y, Taniguchi H, Iwamoto Y. Peri-operative blood loss and extent of fused vertebrae in surgery for adolescent idiopathic scoliosis. Fukuoka Igaku Zasshi. 2011;102(1):8-13.

  11. Koerner JD, Patel A, Zhao C, Schoenberg C, Mishra A, Vives MJ, et al. Blood loss during posterior spinal fusion for adolescent idiopathic scoliosis. Spine. 2014;39(18):1479-87.

  12. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006;355:1303-5.

  13. Kumar A. Perioperative management of anemia: limits of blood transfusion and alternatives to it. Cleveland Clinic journal of medicine. 2009;76(Suppl 4):S112-8.

  14. Soviero F, Geraci A, Termine S, Sanfilippo A, Maritano RM, D'Arienzo M, et al. Bleeding in orthopaedic surgery: the role of blood transfusion and erythropoietin alpha. Acta bio-medica: Atenei Parmensis. 2010;81(2):125-9.

  15. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-64. [Erratum, Blood 2005;105:2257.]

  16. Schouten ES, van de Pol AC, Schouten AN, Turner NM, Jansen NJ, Bollen CW. The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis. Pediatric critical care medicine. 2009;10(2):182-90.

  17. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115(22):2801-13.

  18. Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM. A systematic review and metaanalysis of the topical administration of tranexamic acid in total hip and knee replacement. The bone & joint journal. 2014;96-B(8):1005-15.

  19. Meng Wang, Xin-Feng Zheng, Lei-Sheng Jiang. Efficacy and safety of antifibrinolytic agents in reducing perioperative blood loss and transfusion requirements in scoliosis surgery: A systematic review and meta-analysis. PLOS ONE. 2015 Sep;10(9): e0137886.

  20. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-65.

  21. González Alfonso O, Hidalgo Menéndez PA, Mesa Hurtado JC, Lorenzo Corcho JA, Fajardo Egozcue I. Reacción anafiláctica a la aprotinina con dosis de prueba negativa. Informe de dos pacientes. Cardiocentro de Santa Clara. Servicio de Anestesia y Reanimación. 2014.

  22. Klein HG. How safe is blood, really? Biologicals. 2010;38(1):100-4.

  23. Frisch NB, Wessell NM, Charters MA. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty. 2014;29(9 Suppl):189-92.

  24. Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and metaanalysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011;93(1):39-46.

  25. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Arch Surg. 1998;133(4):442-7.

  26. Hall TS, Sines JC, Spotnitz AJ. Hemorrhage related reexploration following open heart surgery: the impact of pre-operative and post-operative coagulation testing. Cardiovasc Surg. 2002;10:146-53.

  27. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99:923-30.

  28. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JC, Nieuwenhuis HK, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175-9.

  29. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-90.

  30. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-5. [Erratum, Lancet 2003;361:1138.]

  31. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777-85.

  32. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol. 1975;30:81- 93.

  33. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of hemophilia and von Willebrand's diseases. Lancet. 1977;1:869-72.

  34. Kobrinsky N, Gerrard J, Watson C, Israels E, Cheang M, Bishop A, et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; 323(8387):1145-8.

  35. Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982;59:1272-8.

  36. Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood. 1984;64:229-36.

  37. Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth. 2003;50:14-20.

  38. Theroux MC, Corddry DH, Tietz AE, Miller F, Peoples JD, Kettrick RG. A study of desmopressin and blood loss during spinal fusion for neuromuscular scoliosis: a randomized, controlled, double-blinded study. Anesthesiology. 1997;87:260-7.

  39. Alanay A, Acaroglu E, Ozdemir O, Ercelen O, Bulutcu E, Surat A. Effects of deamino-8-D-arginine vasopressin on blood loss and coagulation factors in scoliosis surgery: a double-blind randomized clinical trial. Spine. 1999;24:877-82.

  40. Hatzidakis AM, Mendlick RM, McKillip T, Reddy RL, Garvin KL et al. Preoperative autologous donation for total joint arthroplasty. An analysis of risk factors for allogenic transfusion. J Bone Joint Surg Am. 2000;82(1):89-100.

  41. Guerin S, Collins C, Kapoor H, McClean I, Collins D. Blood transfusion requirement prediction in patients undergoing primary total hip and knee arthroplasty. Transfus Med. 2007;17(1):37-43.

  42. Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):459-69.

  43. Mesa-Ramos F, Mesa-Ramos M, Maquieira-Canosa C, Carpintero, P. Predictors for blood transfusion following total knee arthroplasty: a prospective randomised study. Acta Orthop Belg. 2008;74(1): 83-9.

  44. Levine BR, Haughom B, Strong B, Hellman M, Frank RM . Blood management strategies for total knee arthroplasty. J Am Acad Orthop Surg 2014;22(6):361-71.

  45. Noticewala MS, Nyce JD, Wang W, Geller JA, Macaulay W. Predicting need for allogeneic transfusion after total knee arthroplasty. J Arthroplasty. 2012;27(6):961-7.

  46. Browne JA, Adib F, Brown TE, Novicoff WM. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty. 2013;28(8 Suppl):34-7.

  47. Pola E, Papaleo P, Santoliquido A, Gasparini G, Aulis L, De Santis E, et al. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg Am. 2004;86-A(1):57-61.

  48. Scott BH, Seifert FC, Glass PS, Grimson, R. Blood use in patients undergoing coronary artery bypass surgery: impact of cardiopulmonary bypass pump, hematocrit, gender, age, and body weight. Anesth Analg. 2003;97(4):958-63.

  49. Walsh M, Preston C, Bong M, Patel V, Di Cesare PE. Relative risk factors for requirement of blood transfusion after total hip arthroplasty. J Arthroplasty. 2007;22(8):1162-7.

  50. Aderinto J, Brenkel IJ. Pre-operative predictors of the requirement for blood transfusion following total hip replacement. J Bone Joint Surg Br. 2004;86(7):970-3.

  51. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-14.

  52. Namba RS, Paxton L, Fithian DC, Stone, ML. Obesity and perioperative morbidity in total hip and total knee arthroplasty patients. J Arthroplasty. 2005;20(7 Suppl 3):46-50.

  53. Amin AK, Clayton RA, Patton JT, Gaston M, Cook RE, Brenkel IJ. Total knee replacement in morbidly obese patients. Results of a prospective, matched study. J Bone Joint Surg Br. 2006;88(10):1321-6.

  54. Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am. 2007;89(1):33-8.

  55. Hrnack SA, Skeen N, Xu T. Correlation of body mass index and blood loss during total knee and total hip arthroplasty. Am J Orthop. 2012;41(10):467-71.

  56. Ahmed I, Chan JK, Jenkins P, Brenkel I, Walmsley P. Estimating the transfusion risk following total knee arthroplasty. Orthopedics. 2012;35(10):e1465-71.

  57. Salido JA, Marin LA, Gomez LA, Zorrilla P, & Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am. 2002;84-A(2):216-20.

  58. Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop. 2007;31(1):39-44.

  59. Cushner FD, Friedman RJ. Blood loss in total knee arthroplasty. Clin Orthop Relat Res. 1991;(269):98-101.

  60. Grosflam JM, Wright EA, Cleary PD, Katz JN. Predictors of blood loss during total hip replacement surgery. Arthritis Care Res. 1995;8(3):167-73.

  61. Bierbaum BE, Callaghan JJ, Galante JO. An analysis of blood management in patients having a total hip or knee arthroplasty. JBJ Surg (A). 1999;81(1):2-10.

  62. Hrnack SA, Skeen N, Xu T. Correlation of body mass index and blood loss during total knee and total hip arthroplasty. Am J Orthop. 2012;41(10):467-71.

  63. Aglietti P, Baldini A, Vena LM. Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orth Relat Res. 2000;(371):169-77.

  64. Vandenbussche E, Duranthon LD, Couturier M, Pidhorz L, Augereau B. The effect of tourniquet use in total knee arthroplasty. Int Orthop. 2002;26(5):306.9.

  65. Jones HW, Savage L, White C, Goddard R, Lumley H, Kashif F, et al. Postoperative autologous blood salvage drains -are they useful in primary uncemented hip and knee arthroplasty? A prospective study of 186 cases. Acta Orthop Belg. 2004;70(5):466- 73.

  66. Zan PF, Yang Y, Fu D, Yu X, Li GD. Releasing of tourniquet before wound closure or not in total knee arthroplasty: a meta-analysis of randomized controlled trials. J Arthroplasty. 2015;30(1):31-7.

  67. Keith I. Anaesthesia and blood loss in total hip replacement. Anaesthesia. 1977;32(5):444-50.

  68. Stevens RD, Van Gessel E, Flory N, et al. Lumbar plexus block reduces pain and blood loss associated with total hip arthroplasty. Anesthesiology. 2000;93(1):115-21.

  69. Guay J. The effect of neuraxial blocks on surgical blood loss and blood transfusion requirements: a meta-analysis. J Clin Anesth. 2006;18(2):124-8.

  70. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S , Lonner JH . A metaanalysis of thromboembolic prophylaxis following elective total hip arthroplasty. JBJ Surg (A). 2000;82-A(7):929-38.

  71. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162(16):1833-40.

  72. Colwell CW Jr, Collis DK, Paulson R. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. JBJ Surg (A). 1999;81(7):932-40.

  73. Warwick D, Harrison J, Glew D, Mitchelmore A, Peters TJ, Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. JBJ Surg (A). 1998;80(8):1158-66.




2020     |     www.medigraphic.com